Table 2.
Plasma levels of classical and alternative renin-angiotensin system (RAS) components in patients with compensated (cACLD) and decompensated cirrhosis (dACLD).
| Parameter | cACLD (n = 13) | dACLD (n = 12) | p-value |
|---|---|---|---|
| PRA-S, pmol L−1 (IQR) | 51.5 (150.0) | 489.7 (710.1) | 0.001 |
| ACE-S, (pmol L−1) × (pmol L−1) (IQR) | 6.6 (4.4) | 3.4 (2.5) | 0.022 |
| Ang I, pmol L−1 (IQR) | 12.4 (14.4) | 93.1 (317.8) | < 0.001 |
| Ang II, pmol L−1 (IQR) | 46.2 (136.4) | 343.7 (666.4) | 0.016 |
| Ang 1–7, pmo L−1 (IQR) | 3.0 (0.0) | 16.1 (68.3) | < 0.001 |
| Undetectable Ang 1–7, n (%) | 12 (92.3%) | 2 (16.7%) | < 0.001 |
| Ang 1–5, pmol L−1 (IQR) | 6.6 (12.8) | 33.5 (114.5) | < 0.001 |
| Ang III, pmol L−1 (IQR) | 2.5 (0.9) | 3.1 (10.5) | 0.309 |
| Ang IV, pmol L−1 (IQR) | 2.0 (2.8) | 5.0 (16.6) | 0.141 |
| Aldosterone, pg mL−1 (IQR)a | 84.0 (100.7) | 383.6 (499.0) | 0.007 |
ACE-S angiotensin converting enzyme surrogate, Ang angiotensin, cACLD compensated advanced chronic liver disease, dACLD decompensated advanced chronic liver disease, IQR interquartile range, PRA-S plasma renin activity surrogate, RAS renin–angiotensin system.
aAvailable in n = 14 patients (cACLD: n = 7; dACLD: n = 7).